Literature DB >> 12681268

The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.

Peter Littlejohns1, David Barnett, Carole Longson.   

Abstract

The National Institute for Clinical Excellence (NICE) was established to ensure faster and more equitable uptake of new technologies by the NHS, through the provision of guidance on clinical and cost-effectiveness. The treatment of cancer is one of the UK government's priority areas and a range of guidance products have been developed by NICE to support implementation of national plans for managing patients with cancer in England and Wales. In its first 3 years, NICE's main activity was the "Technology Appraisals Programme" and it has created considerable interest and some controversy. 15 (out of a total of 56) technology appraisals related to oncology have been completed and another four are in preparation. The open, transparent, and inclusive approach NICE has adopted in reaching its decisions highlights the difficult ethical issues that need to be addressed in seeking to balance individual desires with public-health requirements. In this review we describe the process of appraising technologies, and address the recent criticism of the appraisal programme with regard to treatment of patients with cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12681268     DOI: 10.1016/s1470-2045(03)01036-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  5 in total

1.  The average body surface area of adult cancer patients in the UK: a multicentre retrospective study.

Authors:  Joseph J Sacco; Joanne Botten; Fergus Macbeth; Adrian Bagust; Peter Clark
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

2.  Introducing the patient's perspective in hospital health technology assessment (HTA): the views of HTA producers, hospital managers and patients.

Authors:  Marie-Pierre Gagnon; Marie Desmartis; Johanne Gagnon; Michèle St-Pierre; François-Pierre Gauvin; Marc Rhainds; Dolorès Lepage-Savary; Martin Coulombe; Mylène Tantchou Dipankui; France Légaré
Journal:  Health Expect       Date:  2012-10-10       Impact factor: 3.377

3.  International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.

Authors:  Carol Sunghye Lim; Yun-Gyoo Lee; Youngil Koh; Dae Seog Heo
Journal:  BMC Health Serv Res       Date:  2014-11-29       Impact factor: 2.655

4.  Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.

Authors:  Victoria Charlton
Journal:  Health Care Anal       Date:  2021-11-08

5.  NICE cancer guidance: a description of the institute's clinical guideline programme.

Authors:  P Littlejohns; M Eccles; G Leng
Journal:  Br J Cancer       Date:  2003-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.